MetaCap

Cocrystal Pharma (COCP) vs TransCode Therapeutics (RNAZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cocrystal Pharma (COCP) has outperformed TransCode Therapeutics (RNAZ) over the past year, gaining 5.6% versus a loss of 86.6%. Over five years, COCP leads with a -91.8% price change compared with -100.0% for RNAZ. TransCode Therapeutics is the larger company by market cap ($20.1 million vs $18.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COCP+5.56%RNAZ-86.57%
+82%-6%-95%
Nov 21, 20251 yearNov 20, 2026
COCP-90.35%RNAZ-100.00%
+24%-41%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COCP versus RNAZ key metrics
MetricCOCPRNAZ
Share price$0.95$1.16
Market cap$18.30M$20.07M
1-day change-2.05%-10.77%
YTD return-3.06%-83.02%
1-year return+5.56%-86.57%
5-year return-91.84%-100.00%
EPS (TTM)$-0.76$-47.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-8.83M$-34.66M
52-week high$2.03$12.60
52-week low$0.76$1.01
Distance from 52-week high-53.20%-90.79%
Analyst consensusnone—
Avg. price target upside+847.37%—
Average volume40.65K52.03K
Shares outstanding19.26M17.30M
Employees1012
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • COCP has outperformed RNAZ by 92.1 percentage points over the past year.

About Cocrystal Pharma

COCP stock →

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About TransCode Therapeutics

RNAZ stock →

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

COCP vs RNAZ FAQ

Which is bigger, Cocrystal Pharma or TransCode Therapeutics?

TransCode Therapeutics (RNAZ) is larger, with a market capitalization of $20.07M compared with $18.30M for Cocrystal Pharma (COCP).

Which stock has performed better over the past year, COCP or RNAZ?

COCP returned +5.56% over the past 12 months, compared with -86.57% for RNAZ (price return, excluding dividends). Past performance does not predict future results.

Are Cocrystal Pharma and TransCode Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons